Anesiva out-licensed all rights to its NF-kappa B Decoy program to Transcription Factor Therapeutics (TFT). The deal could be worth up to $114 million if two products are commercialized.
This fee covers an upfront license fee, with additional payments dependent on development and regulatory milestones. Anesiva is also be entitled to royalty payments upon successful commercialization of any drug candidate(s).
The transaction includes clinical drug candidate Avrina™. TFT will be responsible for the future development of Avrina, an inhibitor of NF-kappa that has already been assessed in a Phase I study for treatment of atopic dermatitis. The firm hopes to commence a trial in IBD next year.
In addition, IP associated with the NF-kB Decoy program, which has applications in eczema, rheumatoid arthritis, and asthma, will be transferred to TFT.